Abiopharma

New Form 6-K - Enlivex Therapeutics Ltd. Filed: 2025-09-09 AccNo: 0001213900-25-085857 Size: 32 KB

New Form 8-K - Salarius Pharmaceuticals, Inc. Filed: 2025-09-09 AccNo: 0001615219-25-000125 Size: 186 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

New Form 8-K - TENAX THERAPEUTICS, INC. Filed: 2025-09-09 AccNo: 0001654954-25-010510 Size: 198 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

New Form 8-K - REVELATION BIOSCIENCES, INC. Filed: 2025-09-09 AccNo: 0001810560-25-000006 Size: 4 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Hyperion DeFi Strengthens Leadership Team With Key Appointments to Accelerate DeFi Strategy

AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation

Agilent Technologies, Inc. - Agilent Refurbishment Centers Achieve Top-Level My Green Lab Certification

New Form 8-K - ArriVent BioPharma, Inc. Filed: 2025-09-09 AccNo: 0001558370-25-011954 Size: 200 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form SCHEDULE 13D - ORASURE TECHNOLOGIES INC Filed: 2025-09-09 AccNo: 0000902664-25-004014 Size: 38 KB

Butterfly Network, Inc. - Butterfly Network Appoints Victor Ku as Chief Technology Officer

New Form 144 - UroGen Pharma Ltd. Filed: 2025-09-09 AccNo: 0001976408-25-000295 Size: 4 KB

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program